Social Media Ideas for Adneuris Therapeutics

Tris Pharma debuts Adneuris Therapeutics in new approach to pain management

Tris Pharma launched Adneuris Therapeutics on July 9 to advance a vision for pain medicine through the development and future commercialization of cebranopadol, its lead investigat...

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

Phase 3 Failure Keeps AstraZeneca and Ionis Out of a Growing Heart Disease Market

AstraZeneca and Ionis Pharmaceuticals drug eplontersen, brand name Wainua, failed a Phase 3 test in cardiomyopathy caused by transthyretin amyloidosis. More details will be shared...

FDA approves Tryngolza to reduce acute pancreatitis risk

The FDA has approved olezarsen as the first and only therapy, alongside diet, to lower triglycerides and acute pancreatitis risk in patients with severe hypertriglyceridemia, accor...

ADC Therapeutics

ADC Therapeutics Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/adc-therapeutics.665008/...

Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data

Endologix acquires thrombectomy system from Surmodics

Endologix, a medtech that focuses on treatments for vascular diseases, expanded its offerings with the purchase of a mechanical thrombectomy system from Surmodics.

A Metabolic Disease Posing Severe Pancreatic Risks Gets Its First FDA-Approved Therapy

Ionis Pharmaceuticals’ Tryngolza is now the first approved therapy for treating severe hypertriglyceridemia, a prevalent chronic metabolic disorder that can lead to acute pancreati...

Apogee Therapeutics: Targeting Atopic Dermatitis

AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio...

Vedana Therapeutics surfaces with $46M to develop next generation of migraine prevention therapies

Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s subcutaneously delivered antibodies for migraine prevention.

City banks nearly $100M for next-gen RNAi drugs

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon fol...

ATP Platform Adaptive Trial Speeds Up Dementia Research

UCSF launches the historic ATP clinical trial, testing a combination of donanemab and the AADvac1 vaccine to treat pre-symptomatic Alzheimer's.

Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover

Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies abou...

A migraine drugmaker heads to the public markets through reverse merger

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing...

Ethyreal starts up with $101M and takes aim at a pair of immune diseases

The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 developmen...

ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche hel...

Relay drug shows early promise against rare blood vessel diseases

While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments...

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

Atreon Orthopedics® and RenovoDerm® Announce Merger

Positions Synthetic Portfolio as a Leading Solution for Tissue Repair and Remodeling in Substantial Markets Enables Autobiologic™ Platform…

Rapport ‘fully prepared’ to launch seizure drug solo, CEO says

In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brai...

Bain-backed bone specialist Angitia drops lead spinal fusion candidate

Coming on the heels of a $130 million fundraising round just four months ago, bone-focused Angitia Biopharmaceuticals has pivoted away from its lead asset to structure its pipeline...

Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout

Based in San Diego, Crinetics focuses on discovering, developing, and commercializing therapeutics for endocrine diseases. The company’s first marketed drug Palsonify® (paltusotine...